HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Christoph T Ellebrecht Selected Research

Immunoglobulin G (IgG)

1/2022Pemphigus and Pemphigoid: From Disease Mechanisms to Druggable Pathways.
12/2020Antigen-specific B cell depletion for precision therapy of mucosal pemphigus vulgaris.
1/2018Autoreactive IgG and IgA B Cells Evolve through Distinct Subclass Switch Pathways in the Autoimmune Disease Pemphigus Vulgaris.
5/2017Pemphigus.
1/2016Pathogenicity and Epitope Characteristics Do Not Differ in IgG Subclass-Switched Anti-Desmoglein 3 IgG1 and IgG4 Autoantibodies in Pemphigus Vulgaris.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Christoph T Ellebrecht Research Topics

Disease

14Pemphigus (Pemphigus Vulgaris)
01/2022 - 04/2014
8Autoimmune Diseases (Autoimmune Disease)
01/2023 - 04/2014
4Blister (Bulla)
12/2020 - 01/2016
2Psoriasis (Pustulosis Palmaris et Plantaris)
02/2024 - 01/2021
2Bullous Pemphigoid (Pemphigoid)
11/2022 - 01/2022
2Communicable Diseases (Infectious Diseases)
01/2021 - 12/2020
2Infections
10/2017 - 06/2015
2Skin Diseases (Skin Disease)
01/2017 - 04/2016
2Epidermolysis Bullosa Acquisita (Acquired Epidermolysis Bullosa)
04/2016 - 11/2011
2Inflammation (Inflammations)
04/2016 - 06/2015
1Psoriatic Arthritis
02/2024
1Myasthenia Gravis
01/2023
1Muscle Weakness
01/2023
1Lichen Planus (Lichen Ruber Planus)
11/2022
1COVID-19
01/2021
1HIV Infections (HIV Infection)
10/2017
1Acantholysis
05/2017
1Carcinoma (Carcinomatosis)
05/2017
1Neoplasms (Cancer)
01/2016
1Pathologic Complete Response
12/2014

Drug/Important Bio-Agent (IBA)

12AutoantibodiesIBA
01/2023 - 04/2014
7Desmoglein 3IBA
12/2020 - 04/2014
6AntigensIBA
01/2022 - 01/2016
5Immunoglobulin G (IgG)IBA
01/2022 - 01/2016
4AutoantigensIBA
01/2023 - 01/2016
4DesmogleinsIBA
01/2022 - 04/2014
3Cadherins (E-Cadherin)IBA
05/2017 - 04/2014
3AntibodiesIBA
01/2017 - 11/2011
2Complement System Proteins (Complement)IBA
01/2022 - 11/2011
2EpitopesIBA
12/2020 - 01/2016
2Chimeric Antigen ReceptorsIBA
07/2016 - 01/2016
2Collagen Type VIIIBA
04/2016 - 11/2011
1VaccinesIBA
02/2024
1Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
01/2023
1myasthenia gravis anti-skeletal muscle antibody (ASMA)IBA
01/2023
1Immune Checkpoint InhibitorsIBA
11/2022
1B7-H1 AntigenIBA
11/2022
1Apoptosis Regulatory ProteinsIBA
11/2022
1Immunoglobulin E (IgE)IBA
01/2022
1COVID-19 VaccinesIBA
01/2021
1Immunoglobulin A (IgA)IBA
01/2018
1Protein Isoforms (Isoforms)IBA
05/2017
1GlucocorticoidsIBA
05/2017
1Capsid Proteins (Capsid Protein)IBA
01/2016
1tisagenlecleucelIBA
01/2016
1Interleukin-10 (Interleukin 10)IBA
06/2015
1CytokinesIBA
06/2015
1Rituximab (Mabthera)FDA Link
12/2014
1veltuzumabIBA
12/2014
1Investigational DrugsIBA
12/2014
1PlakophilinsIBA
04/2014
1Proteins (Proteins, Gene)FDA Link
11/2011

Therapy/Procedure

7Therapeutics
02/2024 - 12/2014
3Immunotherapy
11/2022 - 01/2016
2Critical Care (Surgical Intensive Care)
01/2021 - 12/2020